Nabriva Therapeutics AG (NASDAQ:NBRV) – Research analysts at Gabelli boosted their FY2017 earnings estimates for shares of Nabriva Therapeutics AG in a research report issued on Tuesday. Gabelli analyst K. Kedra now anticipates that the biotechnology company will earn ($2.40) per share for the year, up from their previous forecast of ($2.65). Gabelli also issued estimates for Nabriva Therapeutics AG’s FY2018 earnings at ($2.25) EPS, FY2019 earnings at ($2.05) EPS, FY2020 earnings at ($1.20) EPS and FY2021 earnings at $0.10 EPS.

Other equities analysts have also issued research reports about the stock. SunTrust Banks, Inc. boosted their target price on shares of Nabriva Therapeutics AG from $20.00 to $24.00 and gave the company a “buy” rating in a report on Monday. Zacks Investment Research upgraded shares of Nabriva Therapeutics AG from a “hold” rating to a “buy” rating and set a $11.00 target price on the stock in a report on Saturday, May 27th. Wedbush restated an “outperform” rating and issued a $21.00 target price (up previously from $13.00) on shares of Nabriva Therapeutics AG in a report on Monday. Cantor Fitzgerald assumed coverage on shares of Nabriva Therapeutics AG in a report on Thursday, June 22nd. They issued a “buy” rating and a $16.00 target price on the stock. Finally, HC Wainwright restated a “buy” rating and issued a $16.00 target price on shares of Nabriva Therapeutics AG in a report on Friday, June 30th. One research analyst has rated the stock with a sell rating, one has given a hold rating and seven have issued a buy rating to the company. The company presently has an average rating of “Buy” and a consensus target price of $19.13.

COPYRIGHT VIOLATION NOTICE: “FY2017 EPS Estimates for Nabriva Therapeutics AG Lifted by Gabelli (NBRV)” was published by Daily Political and is the property of of Daily Political. If you are reading this story on another site, it was stolen and republished in violation of United States and international copyright and trademark legislation. The legal version of this story can be viewed at https://www.dailypolitical.com/2017/09/21/fy2017-eps-estimates-for-nabriva-therapeutics-ag-lifted-by-gabelli-nbrv.html.

Shares of Nabriva Therapeutics AG (NASDAQ:NBRV) opened at 8.26 on Thursday. The company’s market cap is $221.68 million. The company has a 50 day moving average of $9.01 and a 200-day moving average of $10.19. Nabriva Therapeutics AG has a 52-week low of $3.52 and a 52-week high of $14.10.

Nabriva Therapeutics AG (NASDAQ:NBRV) last released its quarterly earnings data on Monday, August 7th. The biotechnology company reported ($0.54) EPS for the quarter, beating the Zacks’ consensus estimate of ($5.83) by $5.29. The firm had revenue of $1.05 million during the quarter, compared to the consensus estimate of $1.34 million.

In related news, major shareholder Vivo Capital Viii, Llc purchased 52,631 shares of the firm’s stock in a transaction on Monday, September 18th. The stock was purchased at an average cost of $9.46 per share, with a total value of $497,889.26. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, major shareholder Hbm Healthcare Investments (Ca sold 8,558 shares of Nabriva Therapeutics AG stock in a transaction on Thursday, June 29th. The shares were sold at an average price of $10.96, for a total transaction of $93,795.68. Following the completion of the sale, the insider now directly owns 2,591,396 shares of the company’s stock, valued at $28,401,700.16. The disclosure for this sale can be found here. In the last 90 days, insiders sold 279,000 shares of company stock worth $2,870,869. 2.75% of the stock is owned by company insiders.

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Wellington Management Group LLP increased its stake in Nabriva Therapeutics AG by 9.9% in the first quarter. Wellington Management Group LLP now owns 2,154,261 shares of the biotechnology company’s stock valued at $25,830,000 after purchasing an additional 193,951 shares in the last quarter. Almanack Investment Partners LLC. increased its stake in Nabriva Therapeutics AG by 482.2% in the second quarter. Almanack Investment Partners LLC. now owns 907,183 shares of the biotechnology company’s stock valued at $1,633,000 after purchasing an additional 751,366 shares in the last quarter. Nationwide Fund Advisors increased its stake in Nabriva Therapeutics AG by 4.6% in the second quarter. Nationwide Fund Advisors now owns 180,924 shares of the biotechnology company’s stock valued at $2,032,000 after purchasing an additional 7,924 shares in the last quarter. Finally, Royal Bank of Canada increased its stake in Nabriva Therapeutics AG by 19.6% in the second quarter. Royal Bank of Canada now owns 52,807 shares of the biotechnology company’s stock valued at $553,000 after purchasing an additional 8,650 shares in the last quarter. 68.56% of the stock is owned by hedge funds and other institutional investors.

Nabriva Therapeutics AG Company Profile

Nabriva Therapeutics plc is a clinical stage biopharmaceutical company. The Company is engaged in engaged in the research and development of novel anti-infectives to treat serious infections, with a focus on the pleuromutilin class of antibiotics. The Company’s medicinal chemistry has enabled targeted discovery of novel pleuromutilins, including both intravenous and oral formulations of its lead product candidate, lefamulin.

Earnings History and Estimates for Nabriva Therapeutics AG (NASDAQ:NBRV)

Receive News & Ratings for Nabriva Therapeutics AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics AG and related companies with MarketBeat.com's FREE daily email newsletter.